CYT387 (momelotinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CYT387 (momelotinib), covering 2019-02-01 to 2019-02-01. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) [Phase 1, Phase 2]